标题
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
作者
关键词
-
出版物
npj Breast Cancer
Volume 7, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-05-12
DOI
10.1038/s41523-021-00258-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
- (2020) Francesco Schettini et al. CANCER TREATMENT REVIEWS
- Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer
- (2020) Shuai Gao et al. NATURE GENETICS
- A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
- (2019) Bora Lim et al. BRITISH JOURNAL OF CANCER
- Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1
- (2019) Leiming Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer
- (2018) Kyla A.L. Collins et al. Oncotarget
- Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
- (2018) Xin Li et al. Molecular Cancer
- HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
- (2017) Antonio Llombart-Cussac et al. LANCET ONCOLOGY
- Salmon provides fast and bias-aware quantification of transcript expression
- (2017) Rob Patro et al. NATURE METHODS
- PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
- (2017) Eneda Toska et al. SCIENCE
- Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex
- (2017) Jon S. Zawistowski et al. Cancer Discovery
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy
- (2017) Debora Fumagalli et al. JAMA Oncology
- Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance
- (2016) Richard Marcotte et al. CELL
- Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer
- (2016) V. Varadan et al. CLINICAL CANCER RESEARCH
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
- (2016) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
- (2016) Maxim V. Kuleshov et al. NUCLEIC ACIDS RESEARCH
- FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
- (2016) Xiaoyong Fu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- TNFα Signaling Exposes Latent Estrogen Receptor Binding Sites to Alter the Breast Cancer Cell Transcriptome
- (2015) Hector L. Franco et al. MOLECULAR CELL
- The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value
- (2015) Pascale A. Cohen et al. Oncotarget
- Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
- (2015) Timothy J. Stuhlmiller et al. Cell Reports
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Cross-regulation between FOXA1 and ErbB2 Signaling in Estrogen Receptor-Negative Breast Cancer
- (2015) Ali Naderi et al. NEOPLASIA
- Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R
- (2014) Xing-Ming Ye et al. BMC CANCER
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
- (2014) Aleix Prat et al. JNCI-Journal of the National Cancer Institute
- An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer
- (2014) Michael L Gatza et al. NATURE GENETICS
- FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS
- (2014) Yawei Liu et al. NATURE MEDICINE
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
- (2013) Edward Y Chen et al. BMC BIOINFORMATICS
- PDEF Promotes Luminal Differentiation and Acts as a Survival Factor for ER-Positive Breast Cancer Cells
- (2013) Gilles Buchwalter et al. CANCER CELL
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
- (2013) Ethan V. Abel et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- FoxA1 is a Key Mediator of Hormonal Response in Breast and Prostate Cancer
- (2012) Jessica L. L. Robinson et al. Frontiers in Endocrinology
- SOX10 directly modulates ERBB3 transcription via an intronic neural crest enhancer
- (2011) Megana K Prasad et al. BMC DEVELOPMENTAL BIOLOGY
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
- (2011) Min Ni et al. CANCER CELL
- HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance
- (2011) Xiaoping Huang et al. CANCER LETTERS
- The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium
- (2011) J. M. Balko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients
- (2011) Maurizio Scaltriti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PBX1 Genomic Pioneer Function Drives ERα Signaling Underlying Progression in Breast Cancer
- (2011) Luca Magnani et al. PLoS Genetics
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- FOXA1 is a key determinant of estrogen receptor function and endocrine response
- (2010) Antoni Hurtado et al. NATURE GENETICS
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started